Drug Approval | March 07, 2022
NATCO launches first generic version of Revlimid in the US
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
The guidance also urges companies to act quickly to initiate a recall when public health is at risk and to do so prior to completing an investigation into the cause of the problem
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream
The product will be manufactured at Lupin’s facility in Pithampur, India
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Subscribe To Our Newsletter & Stay Updated
